| 000 | 01916naaaa2200325uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/77560 | ||
| 005 | 20220220035007.0 | ||
| 020 | _aintechopen.91507 | ||
| 020 | _a9781839688683 | ||
| 020 | _a9781839688676 | ||
| 020 | _a9781839688690 | ||
| 024 | 7 |
_a10.5772/intechopen.91507 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 072 | 7 |
_aMJCL _2bicssc |
|
| 100 | 1 |
_aArnouk, Hilal _4edt |
|
| 700 | 1 |
_aAbdul Rasool Hassan, Bassam _4edt |
|
| 700 | 1 |
_aArnouk, Hilal _4oth |
|
| 700 | 1 |
_aAbdul Rasool Hassan, Bassam _4oth |
|
| 245 | 1 | 0 | _aAdvances in Precision Medicine Oncology |
| 260 |
_bIntechOpen _c2021 |
||
| 300 | _a1 electronic resource (260 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aRecent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/3.0/ _2cc _4https://creativecommons.org/licenses/by/3.0/ |
||
| 546 | _aEnglish | ||
| 650 | 7 |
_aOncology _2bicssc |
|
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://www.intechopen.com/books/10321 _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/77560 _70 _zDOAB: description of the publication |
| 999 |
_c63367 _d63367 |
||